PEP-Therapy

PEP-Therapy is a private, Paris-based biotech leveraging a novel intracellular drug delivery platform to develop targeted peptide therapies for cancer. The company's lead asset, PEP-010, is in Phase Ia/b trials for recurrent/metastatic solid tumors and recently received FDA Orphan Drug Designation for pancreatic cancer. Backed by international venture capital and strategic partnerships with premier cancer centers, PEP-Therapy aims to address undruggable intracellular targets and improve therapeutic performance.

Proprietary intracellular drug delivery shuttle platform capable of delivering diverse payloads (peptides, proteins, antibodies, nucleic acids) into cells to address previously undruggable targets.

PEP-Therapy competes in the crowded targeted oncology therapy space, facing competition from both large pharma and biotech companies developing antibody-drug conjugates (ADCs), proteolysis-targeting chimeras (PROTACs), and other modality platforms. Its differentiation lies in its peptide-based, cell-penetrating shuttle designed for intracellular targets, a niche with fewer established players but significant technical hurdles.